CN101899443A - Method for regulating and controlling FAF1 (Fas-associated Factor-1) genes, composition and application thereof - Google Patents

Abstract

The invention provides a method for regulating and controlling FAF1 (Fas-associated Factor-1) genes, aiming at inducing apoptosis of cancer cells in cancers such as prostatic cancer and the like by regulating and controlling the expression of the FAF1 genes. The method comprises the steps of giving out miR-24 inhibitors and/or simultaneously mutating binding bites of miR-24 in the FAF1 genes. The invention further provides a pharmaceutical composition containing the miR-24 inhibitors and a kit.

Description

The method and composition of regulation and control FAF1 gene and the purposes of described composition

Technical field

The present invention relates to the miRNA field.Particularly, the present invention relates to the purposes of the method and composition and the described composition of FAF1 gene.

Background technology

MicroRNA is the small molecules non-coding RNA about the endogenous expression of a class, about 22nt, and they are regulated and control target gene by post-transcriptional level.Usually they are regulated and control target gene by the translation of shearing mRNA or inhibition mRNA.Work in a lot of biological processess although have been found that some miRNA, for example control is grown, and the embryo generates, cytodifferentiation is bred and apoptosis, and target gene and the functional study to most miRNA also is not very clear at present.

Apoptosis is a kind of situation of the programmed cell death in the multicellular organisms.Apoptosis embodies variation, the metamorphosis of cell and the death of cell for a series of biochemical indicators in the cell.More and more evidences show miRNA can be in growth course and in some other biological processes the apoptosis of regulating cell.Some miRNAs relevant have also been found simultaneously with apoptosis.But the miRNA of all known modulating apoptosis regulates and control by the 3 ' non-translational region that is attached to target gene.Also be not combined at present the example of target gene mRNA 3 ' non-translational region regional regulating cell apoptosis in addition.

The FAF1 gene is a composition of apoptosis-inducing signal complex body (DISC), although it does not have typical apoptosis structural domain, it can be regulated and control with caspase8 and FADD protein binding pair cell apoptosis.Nearest discovers that at the Jurkat cell, high expression level FAF1 gene all can cause the apoptosis of cell in L cell and the BOSC23 cell under situation about existing without any exogenous apoptosis inducing factor.Existing document reports that stomach organization cell and cervical cancer tissues FAF1 express and descend, and descends relevant with low differentiation of cancer cells and level of apoptosis; The expression of the expression level of FAF1 in Parkinson's disease (PD) patient and Alzheimer (AD) patient's prefrontal cortex (frontal cortex) obviously raises with respect to control group.Existing bibliographical information, " positive expression rate of the FAF1 of stomach organization (37.50%) is starkly lower than cancer beside organism's (62.50%, P＜0.05) and healthy tissues (72.50%, P＜0.01); Low or do not break up stomach organization FAF1 positive expression rate and significantly be lower than senior middle school differentiation stomach organization (73.08% vs 64.29%, P＜0.05).Apoptosis in gastric cancer index relevant with cancer cells differentiation degree, distant metastasis, invasive depth and clinical stages (P all＜0.05).The apoptosis in gastric cancer index that FAF1 expresses negative group significantly is lower than the positive group of FAF1 (P＜0.01).Conclusion: stomach organization cell FAF1 expresses decline, and relevant with level of apoptosis decline with the low differentiation of cancer cells, and the low expression of prompting FAF1 may take place and develop relevant with cancer of the stomach, and influencing cytodifferentiation and apoptosis is its possible mechanism of action." in addition, there is high expression level in known miR-24 in colorectal carcinoma and carcinoma of the pancreas.

Prostate cancer (PCa) is the kinds of tumor of male genitourinary system, and its sickness rate ranks first at American-European countries's height, also is remarkable ascendant trend at the sickness rate of China.In early days, hormonal dependent prostate cancer (HDPC) can reach the purpose of dwindling the knurl body, reducing blood PSA by endocrine therapy, but after treatment 1～2 year, develop to hormone-independent prostate cancer (HIPC) gradually, cause the patient finally to die from the extensive transfer of the insensitive cell of hormone.The treatment of hormone-independent prostate cancer is difficulty relatively, and the meta of chemotherapy total lifetime only is 15.16～26.16 months.Many patients with prostate cancer, especially hormone-independent prostate cancer patient begin to seek alternative medicine.Still do not have special effective treatment for hormone-independent prostate cancer at present, the herbal medicine therapy is one of the most frequently used alternative medicine.Cytokinetics studies confirm that the prostate cancer morbidity is owing to cell proliferation and the unbalance cell number increase that causes of apoptosis.Many scholars make great efforts to seek crucial apoptosis regulator, in the hope of becoming the effective ways of therapeutic advance phase prostate cancer.In addition, the molecular pathway of raising apoptosis also has remarkable effect to the vascularization of minimizing prostate cancer, enhancing tumour to the susceptibility of other treatment (as radiotherapy, chemotherapy etc.).

In recent years, along with the further investigation of people to the apoptosis molecular mechanism, recognize that increasing apoptosis of tumor cells is an effectively approach of treatment tumour, many antineoplastic chemotherapy medicines destroy tumour cell by cytotoxicity, but can produce cross resistance between the chemotherapeutic and reduce chemotherapy effect, and increase toxic action.Exploring the hormone-independent prostate cancer The mechanism of apoptosis and seeking to cause the apoptotic molecular target of hormone-independent prostate cancer is the focus of current hormone-independent prostate cancer correlative study.

Summary of the invention

Prostate cancer DU-145 is the cell strain of the non-dependence of male sex hormone, the application finds to suppress by miR-24-ASO the expression of miR-24, can obviously cause the apoptosis of DU-145 cell, and the DU-145 cell is obviously weakened the tolerance of apoptosis-induced medicine star born of the same parents rhzomorph.Simultaneously, in transfection miR-24-ASO suppress miR-24 expression simultaneously cotransfection pcDNA3.1-FAF1 overexpression Faf1 gene can significantly induce the apoptosis of DU-145 cell and apoptosis rate to reach about 70% after 48 hours.Simultaneously, we have also found to suppress the apoptosis that the expression of miR-24 can inducing cell in the HeLa cell.Up to the present, also there is not to find to regulate and control the miRNA of FAF1 expression level.In this application, we have found that miR-24 can regulate and control the FAF1 gene by the open reading frame zone that is attached to FAF1 mRNA.Simultaneously, the expression of using miR-24-ASO to suppress miR-24 can cause the apoptosis of DU-145 cell and HeLa cell.Experimental result proves that miR-24 can be used as effective target spot of treatment hormone-independent prostate cancer.MiR-24-ASO can be used as the active drug of exploitation treatment hormone-independent prostate cancer even some other cancer simultaneously.

In addition, also can cause a large amount of apoptosis of DU-145 cell (pcDNA3.1-FAF1-M12 in the every hole of transfection 100ng can induce about 34% in 12 orifice plates) at the FAF1 gene (being FAF1-M12) that the seed region of miR-24 binding site has been done same sense mutation after 36 hours.The apoptosis that proof uses FAF1-M12 also can induce prostate cancer cell DU-145 separately.

Therefore, one aspect of the present invention relates to a kind of isolating FAF1 gene, the nucleotide sequence of aminoacid sequence shown in this FAF1 genes encoding SEQ ID NO:2, wherein, there are the described 1650-1670 position of one or more bases and SEQ ID NO:1 and/or 2128-2148 bit base to compare in this nucleotide sequence in the base corresponding to SEQ ID NO:1 1650-1670 position and/or 2128-2148 bit base same sense mutation has taken place.

In a preferred embodiment, the nucleotide sequence of the isolating FAF1 gene of the present invention is shown in SEQ ID NO:1 454-2406 position, but the sequence numbering with SEQ ID NO:1 is as the criterion, and same sense mutation has taken place for 1650-1670 position wherein and/or the one or more Nucleotide in the 2128-2148 position.

In another preferred embodiment, the nucleotide sequence of described FAF1 gene is shown in the 454-2406 position of SEQ ID NO:12.

The present invention relates to the FAF1 gene or the purposes of the isolating FAF1 gene of the present invention in the medicine that preparation is treated or preventing cancer is used of not sudden change on the other hand.In a preferred embodiment, described cancer is the cancer of FAF1 gene unconventionality expression.

In a preferred embodiment, the cancer of described FAF1 gene unconventionality expression is selected from malignant mesothe, hormone-independent prostate cancer, cervical cancer, cancer of the stomach, colorectal carcinoma and carcinoma of the pancreas.

Further aspect of the present invention relates to composition that the miR-24 inhibitor uses in preparation treatment or preventing cancer or the purposes in the test kit.In a preferred embodiment, described cancer is the cancer of FAF1 gene unconventionality expression.

In a preferred embodiment, the described miR-24 inhibitor antisense nucleic acid that is miR-24.In another preferred embodiment, described antisense nucleic acid is shown in SEQ ID NO:4.

In another preferred embodiment, the cancer of described FAF1 gene unconventionality expression is selected from malignant mesothe, hormone-independent prostate cancer, cervical cancer, cancer of the stomach, colorectal carcinoma and carcinoma of the pancreas.

Another aspect of the invention relates to a kind of expression vector, and this expression vector contains the isolating FAF1 gene of the present invention.

The present invention also relates to the method for FAF1 expression of gene in a kind of external regulating cell on the other hand, and this method comprises:

(1) suppress the expression of miR-24 in this cell, and/or (2) implements same sense mutation to the miR-24 binding site in the FAF1 gene; And/or (3) apply FAF1 gene or the described isolating FAF1 gene of claim 1 or the described expression vector of claim 9 of not sudden change; And/or (4) apply FAF1 expression of gene product; Or (5) overexpression miR-24.

Further aspect of the present invention also relates to the antisense nucleic acid of miR-24.In a preferred embodiment, described antisense nucleic acid is shown in SEQ ID NO:4.In another preferred embodiment, described anti sense nucleotide sequence is 5 '-ctGTTCCTgctgAACTGAgcCA-3 ', wherein lowercase represents to lock the position of nucleic acid marking.

The invention still further relates to composition that miR-24 uses in screening treatment or preventing cancer or the purposes in the test kit.In a preferred embodiment, described cancer is the cancer of FAF1 gene unconventionality expression.

Herein, " cancer of FAF1 gene unconventionality expression " refers to that its FAF1 expression of gene is higher or lower than the cancer of the FAF1 expression of gene in the normal cell.Those skilled in the art are easy to judge according to state of the art which kind of is expressed as unconventionality expression.The related cancer of this paper also comprises " cancer of FAF1 gene mediated ", promptly in the generation of cancer, the cancer that forms and/or exist FAF1 gene in the process to participate in.

The present invention comprises that also the nucleotides sequence of aminoacid sequence shown in the separated coding SEQ ID NO:2 is listed in the purposes in the medicine that preparation or screening treatment or preventing cancer use.In a preferred embodiment, described cancer is the cancer of FAF1 gene unconventionality expression.In a preferred embodiment, the nucleotide sequence of aminoacid sequence shown in the described separated coding SEQ ID NO:2 is shown in the 454-2406 position of SEQ ID NO:1.

Others of the present invention will have detailed description hereinafter.The arbitrary combination that it is pointed out that above-mentioned and each concrete feature hereinafter is also within the scope of the invention.

Description of drawings

Fig. 1 shows that downward modulation miR-24 can be apoptosis-induced, and influences the propagation of DU-145 cell.(a) handle the DU-145 cell with 20nMmiR-24-ASO or NC-ASO, with annexin V and iodate third ingot (propidiumiodine) dyeing, measure apoptosis (n=3 ± SE after 48 hours by FACS; * p＜0.01).Downward modulation miR-24 has induced the apoptosis of DU-145 cell.(b) use apoptosis-induced 2 hours (n=3 ± SE of 1 μ M star born of the same parents rhzomorph after 48 hours with 20nM miR-24-ASO or NC-ASO transfection; * p＜0.01).Susceptibility is higher behind the transfection miR-24-ASO.(c), detect cell proliferation (n=3 ± SE) with CCK-8 test kit (Dojindo) in different time points with after 20nMmiR-24-ASO or the NC-ASO transfection.Downward modulation miR-24 has influenced the propagation of DU-145 cell.(d) after cell is handled 20 hours with the concentration of 20nM as mentioned above, the mature form of pro-caspase 8 and caspase 8 is carried out western engram analysis caspase 8 activity.Caspase 8 is activated behind the transfection miR-24-ASO.Each tests triplicate.

Fig. 2 shows that miR-24 passes through target ORF zone and regulates FAF1.(a) use RNA22 software (IBM), there are two miRNA miR-24 binding sites of inferring in the CDS zone of prediction Faf1 mRNA.Shown in be numbered the numbering of the proteic encoding sequence of FAF1.Shown the sequence, binding site of people miR-24 and in conjunction with energy.(b) use the report carrier transfection 293T cell of forming by the Luciferase luciferase, dye the pGL3 report carrier that contains the miR-24 binding sequence at 3 ' non-translational region of luciferase at the 293T transit cell.Simultaneously cotransfection CMV-Renilla luciferase carrier, as internal standard.Compare with NC-mimics, miR-24-mimics reduces the expression (n=3 ± SE of the Luciferase luciferase of the miR-24 binding sequence that contains prediction; * p＜0.01).(c) regulate FAF1 in the miR-24 body.Handle the 293T cell as shown in FIG., reduce the expression of Faf1 in the miR-24-mimics body.Raised the proteic expression level of Faf1 behind the transfection miR-24-ASO.(d) show miR-24 dose-dependent inhibition Faf1 in the 293T cell.With 100ng pcDNA3.1-FAF1 and 1,5,20nM miR-24-mimics cotransfection 293T cell 24 hours, and immunoblotting as mentioned above.(e) show that the Faf1 that the miR-24-mimics transfection with 1nM or 5nM suddenlyd change after 24 hours fails to be reduced.Though can reduce Faf1 a little with 20nM miR-24-mimics transfection, this may be because the insufficient cause in mutational site of Faf1.Each experiment repeats 3 times.

Fig. 3 shows that miR-24 regulates apoptosis by target FAF.Use different agent treated DU-145 cells as shown in the figure, reagent transfection 48 hours is after FACS measures apoptosis (n=3 ± SE, * p＜0.01).The apoptosis that downward modulation miR-24 has not only induced DU-145 is crossed and is expressed the apoptosis that Faf1 has also induced DU-145.When cotransfection pcDNA3.1-FAF1 and miR-24-ASO, the ratio of apoptotic cell increases greatly.Cross and express the apoptosis that FAF1 causes and to save by miR-24-mimics.Above-mentioned data presentation, miR-24 crosses expression and can protect the DU-145 cell that FAF1 inductive apoptosis does not take place, and downward modulation miR-24 can increase the apoptosis of FAF1 inductive DU-145 cell.(for 12 orifice plates, the concentration of carrier transfection is every hole 100ng, and the concentration of mimics and ASO transfection is every hole 20nM).

Fig. 4 shows that miR-24 passes through to regulate apoptosis in conjunction with FAF1 gene ORF zone.Use different agent treated DU-145 cells as shown in FIG..Measure apoptosis (n=3 ± SE, * p＜0.01, * * p＜0.05) with FACS with the reagent transfection after 36 hours.Same sense mutation has been done in use at the miR-24 binding site FAF1 gene (being pCDNA3.1-FAF1-M12) does not have the FAF1 gene of sudden change can induce the DU145 cell more apoptosis to occur than using separately.Cross and express the FAF1 institute inductive apoptosis that miR-24 can not protect the minimizing of DU-145 cell to express sudden change.(for 12 orifice plates, the concentration of carrier transfection is every hole 100ng, and the concentration of mimics and ASO transfection is every hole 20nM).

Fig. 5 shows, downward modulation miR-24 also influences the propagation of HeLa cell and to the susceptibility of star born of the same parents rhzomorph.(a) use 20nM miR-24-ASO or NC-ASO transfection after 48 hours, with 2 hours (n=3 ± SE of 1 μ M star born of the same parents rhzomorph cell death inducing; * p＜0.01).Susceptibility becomes higher behind the transfection miR-24-ASO.(b) breed at different time usefulness CCK-8 kit detection cell behind demonstration transfection 20nMmiR-24-ASO or the NC-ASO (n=3 ± SE).

Fig. 6 shows use Interfer IN transfection reagent transfection 20nM miR-24-ASO in two strain stomach cancer cell HGC-27 and MGC-803 respectively, the observed result of microscopically after 36 hours.

Fig. 7 shows Annexin V-FITC and the PI coloration result and the apoptosis rate of the described experiment of Fig. 6.

X-coordinate, ordinate zou and the scale of facs analysis figure all are identical among Fig. 1 a, Fig. 1 b, Fig. 3 and Fig. 4, Fig. 5, Fig. 7, and X-coordinate is annexin V-FITC, and ordinate zou is PI, and scale is 10 ⁰-10 ⁴Western blot among all figure experiment all with GAPDH as confidential reference items.

Embodiment

The FAF1 gene is called FAS binding factor 1 again, is a composition of apoptosis-inducing signal complex body (DISC), and its nucleotide sequence is shown in SEQ ID NO:1 (Genebank accession number NM_007051), and aminoacid sequence is shown in SEQIDNO:2.454-2406 position among the SEQ ID NO:1 is the open reading frame zone of proteins encoded.In the healthy tissues of FAF1 gene in animals such as most Mammalss such as people and big mouse expression is arranged all, be included in the various cells of the various tissues of Mammals and express, but expression amount can reduce in tumour cells such as malignant mesothe.

A kind of isolating FAF1 gene of first aspect present invention, the nucleotide sequence of aminoacid sequence shown in its coding SEQ ID NO:2, wherein, there are the described 1650-1670 position of one or more bases and SEQID NO:1 and/or 2128-2148 bit base to compare in this nucleotide sequence in the base corresponding to SEQ ID NO:1 1650-1670 position and/or 2128-2148 bit base same sense mutation has taken place.Same sense mutation can be identical, also can be different: the residing position of the base of promptly undergoing mutation can be identical, also can be different; And/or the quantity of the base of undergoing mutation can be identical, also can be different.Preferably, the base quantity of undergoing mutation in each binding site is 1-21, for example be that 2-18,2-15,2-12,2-10,2-8,2-7,2-5 are individual etc.Preferably, described sudden change occurs on the 2nd to the 8th (from 3 ' to 5 ') in two corresponding zones, and promptly sudden change has taken place for 1 in the 2-8 position or several base.

Same sense mutation refers to annex phenomenon because biological genetic codon exists, and behind a certain sequence change, is translated into same seed amino acid in certain original amino acid whose position, promptly is called same sense mutation.When relating to a peptide species, " separation " means that described molecule separates and separates, or do not have the biomacromolecule of other same type substantially from find the naturally occurring whole organism of this molecule.Term " separation " for nucleic acid is: a kind of nucleic acid molecule, and it lacks bonded sequence natural with it wholly or in part; Or a sequence, because its natural existence, but have and its bonded heterologous sequence; Or from the molecule of chromosome segregation.

More specifically, the nucleotide sequence of isolating FAF1 gene of the present invention is shown in SEQ ID NO:1 454-2406 position, but same sense mutation has taken place for 1650-1670 position wherein and/or the one or more Nucleotide in the 2128-2148 position.Described Nucleotide numbering all is to be as the criterion with the numbering among the SEQ ID NO:1.

The same sense mutation that takes place in described 1650-1670 position and the 2128-2148 position can be identical, and also can be different: the residing position of the base of promptly undergoing mutation can be identical, also can be different; And/or the quantity of the base of undergoing mutation can be identical, also can be different.Preferably, the base quantity that same sense mutation takes place in each binding site is 1-21, for example be that 2-18,2-15,2-12,2-10,2-8,2-7,2-5 are individual etc.Preferably, described same sense mutation occurs on the 2nd to the 8th (from 3 ' to 5 ') in two binding site zones, and promptly same sense mutation has taken place for 1 in the 2-8 position or several base.In the FAF1 gene of the present invention, only same sense mutation takes place in any in two binding sites, also can same sense mutation all take place at two binding sites.

In above-mentioned 1650-1670 position and/or 2128-2148 position, take place the same sense mutation, the Nucleotide of other position of FAF1 gene of the present invention, for example the one or more Nucleotide in 454-1649 position, 1671-2127 position and the 2149-2406 position Nucleotide also can be undergone mutation, as long as this sudden change does not have influence on the function that gained FAF1 gene is had in the present invention.Particularly, the present invention also comprises the FAF1 gene of the following proteins of encoding: process replaces, lacks or adds one or several amino acid and still remain with shown in the SEQ ID NO:2 proteic active by protein derived protein shown in the SEQ ID NO:2 in the aminoacid sequence of described 454-1649 position, 1671-2127 position and 2149-2406 position nucleotide coding.

In a preferred embodiment, FAF1 gene of the present invention is shown in the 454-2406 position among the SEQ ID NO:12.

Can adopt prepared in various methods protein of the present invention.Usually with recombinant methods protein of the present invention.Can prepare code book with the standard molecular biology method and invent proteinic polynucleotide.For example, with recombination method can obtain the to encode polynucleotide sequence of above-mentioned molecule, for example by from expressing the cell screening cDNA and the genomic library of this gene, or by this gene of deriving from the known carrier that comprises this gene.Also can synthesize but not clone and prepare interested gene.The codon of available suitable particular sequence digests this molecule.To assemble complete sequence with the eclipsed oligonucleotide of standard method preparation then, and be fitted in the complete encoding sequence.Referring to as Edge (1981) Nature 292:756; Nambair etc. (1984) Science 223:1299; With (1984) J.Biol.Chem.259:6311 such as Jay.

Therefore, can obtain concrete nucleotide sequence from the carrier that carries required sequence, or with various oligonucleotide synthesis methods known in the art, as site-directed mutagenesis and polymerase chain reaction (PCR), synthetic wholly or in part.Referring to as Sambrook, " molecular cloning: laboratory manual " (Molecular Cloning:a Laboratory Manual), second edition, 1989.Specifically, the method that obtains the nucleotide sequence of the required sequence of coding is the eclipsed synthetic oligonucleotide with the annealing supplementary set of conventional automatic polynucleotide synthesizer preparation, connect with suitable dna ligase then, and the nucleotide sequence that connects with the PVR amplification.Referring to as (1991) Proc.Natl.Acad.Sci.USA 88:4084-4088 such as Jayaraman.In addition, also can use the synthetic (Jones etc. of oligonucleotide orientation in the present invention, the enzymatic that the oligonucleotide directed mutagenesis (Riechmann etc., (1988) Science239:1534-1536 such as (1988) Nature 332:323-327 and Verhoeyen) in Nucleotide zone is arranged (1986) Nature 54:75-82), earlier and carry out with the T4DNA polysaccharase is mended the oligonucleotide synthetic (Queen etc. (1989) Proc.Natl.Acad.Sci.USA 86:10029-10033) of flat rubber belting breach.

In case the preparation or separated encoding sequence, just these sequence clones can be gone in any suitable carriers or the replicon.To those skilled in the art, various cloning vectors are known, and the screening of suitable cloning vector is the selection problem.Suitable carriers comprises (but being not to be limited to): plasmid, phage, transposon, clay, karyomit(e) or when reproducible virus when suitable controlling elements combines.

Then cloned sequence is placed under the control of suitable controlling elements, this depends on the system that is used to express.Therefore, encoding sequence can be placed promotor, ribosome bind site (being used for bacterial expression) and randomly under the control of operon, thereby interested dna sequence dna be transcribed among the RNA by suitable transformant.This encoding sequence can comprise or not comprise signal peptide or leader sequence (can be removed at the translation post-treatment by the host subsequently).Referring to as U.S. Patent No. 4,431,739; 4,425,437; 4,338,397.

Except control sequence, can add the adjusting sequence, thus can be with respect to the expression of the growth regulating sequence of host cell.It is well known by persons skilled in the art regulating sequence, and the example comprises that those can cause replying the adjusting sequence that chemistry or physical stimulation (comprising the existence of regulating compound) start or close genetic expression.The regulatory element that also can have other type in the carrier.For example, can use enhancer element to increase the expression level of construction.Example comprises SV40 early gene enhanser (Dijkema etc. (1985) EMBO J.4:761); From the sarcoma viral long terminal repeat of Rous (LTR) deutero-enhancers/promoters (Gorman etc. (1982) Proc.Natl.Acad.Sci.USA79:6777); With from people CMV deutero-element (Boshart etc., (1985) Cell 41:521), as the element (U.S. Patent No. 5,688,688) that comprises in the CMV intron A sequence.Also can be included in the potential energy and the strong promoter of replication orgin, one or more selectable markers of self-replicating in the proper host cell, one or more restriction site, high copy number amount in the expression cassette.

Construction of expression vector, make concrete encoding sequence be arranged in this and have the carrier that is fit to regulate sequence, the position of the encoding sequence relevant with control sequence and orientation make encoding sequence transcribe (that is this encoding sequence of rna polymerase transcribe that, is incorporated into dna molecular in the control sequence) under " control " of control sequence.May need the sequence of coding molecules of interest is modified and realized this purpose.For example, may need in some cases to modify this sequence, thereby make it be connected in the control sequence that is fit to orientation, promptly keep frame.Before being inserted into carrier, control sequence and other are regulated sequence may be connected in encoding sequence.Perhaps, encoding sequence directly can be cloned in the expression vector that has comprised control sequence and suitable restriction site.

One or more Nucleotide by in sequence, insertion sequence and/or alternative this sequence of lacking the interested polypeptide of part coding can prepare proteic mutant of the present invention who is used to analyze or analogue.The method of modified nucleotide sequence is well-known to those skilled in the art as directed mutagenesis etc.Referring to as Sambrook etc., above-mentioned; Kunkel, T.A. (1985) Proc.Natl.Acad.Sci.USA (1985) 82:448; Geisselsoder etc. (1987) BioiTechniques 5:786; Zoller and Smith (1983) Methods Enzymol.100:468; Dalbie-McFarland etc. (1982) Proc.Natl.Acad.Sci USA 79:6409.

This molecule can be expressed in various systems, comprises insect well known in the art, Mammals, bacterium, virus and yeast expression system.For example, insect cell expression system such as rhabdovirus system are well known by persons skilled in the art, are described in as Summers and Smith Texas Aguricultural Experiment Station Bulletin No.1555 (1987).The material and the method that are used for baculovirus/insect cell expression system all can kit form be buied, Invitrogen especially, San Diego CA (" MaxBac " test kit).Similarly, bacterium and mammalian cell expression system also are well known in the art, and its description is seen as Sambrook etc., as above.Yeast expression system also is well known in the art, and the Butterworths as " yeast genetic engineering " (Yeast Genetic Engineering) (editor such as Barr, 1989), London are seen in its description.

Many host cells that are fit to that are used for said system also are known.For example, mammal cell line is known in the art, it comprises the clone of the immortalization that can obtain from American type culture collection (ATCC), as (but being not to be limited to) Chinese hamster ovary cell (CHO), Hela cell, young hamster kidney (BHK) cell, monkey-kidney cells (COS), HEKC, human liver cell cancer cells (as Hep G2), Madin-Darby ox kidney (" MDBK ") cell etc.Similarly, in expression constructs of the present invention, also can use host bacterium, as intestinal bacteria, Bacillus subtilus and suis.Also available in the present invention yeast host is particularly including yeast saccharomyces cerevisiae (Saccharomyces cerevisiae), maltose candiyeast (Candida maltosa), Candida albicans (Candida albicans), multiple-shaped nuohan inferior yeast (Hansenula polymorpha), Kluyveromyces fragilis (Kluyveromyces fragilis), Kluyveromyces lactis (Kluyveromyces lactis), season is Meng Shi pichia spp (Pichia guillerimondii) also, pichia pastoris phaff (Pichia pastoris), grain wine fragmentation sugar yeast (Schizosaccharomyces pombe) and yarrowia lipolytica.The insect cell that can use with baculovirus expression system is particularly including Aedes aegypti (Aedes aegypti), Autographa californica multicapsid nucleopolyhedrosisvirus (Autographa californica), silkworm (Bombyx mori), black-tailed fruit flies (Drosophila melanogaster), fall army worm (Spodoptera frugiperda) and cabbage looper (Trichoplusia ni).

Send the method for passing with range gene well known in the art, the nucleic acid molecule that comprises interested nucleotide sequence stably can be integrated on the stable additive type element in the host cell gene group or in proper host cell and keep.Referring to as U.S. Patent No. 5,399,346.

According to selected expression system and host, under the condition of marking protein, cultivation prepares this molecule with aforesaid expression vector transformed host cells.Isolate expressed protein and purifying from host cell then.If expression system with protein secreting in substratum, then directly from the substratum purified product.If not excretory, then separate from cell pyrolysis liquid.The culture condition that is fit to and the selection of recovery method all are within those skilled in the art's ability.

Therefore, the present invention also comprises and contains FAF1 expression carrier of the present invention.

Second aspect present invention relates to the method for regulation and control FAF1 genetic expression, and this method comprises the expression of the miR-24 of controlled plant.

MiR-24 is a microRNA very big with the human tumor dependency, and its nucleotides sequence is classified 5 '-UGGCUCAGUUCAGCAGGAACAG-3 ' (SEQ ID NO:3) as.Prior art finds that miR-24 not only can suppress the expression of cancer suppressor gene p16, and it also has unconventionality expression in some tumor types.Our miR-24 that discovers can regulate and control the FAF1 gene by two binding sites on the ORF frame that is attached to FAF1.These two sites are respectively 1650-1670 position and 2128-2148 position in the present position in SEQ IDNO:1.Usually, a miR-24 is in conjunction with a site.Under the situation with some site mutations of FAF1 gene, single miR-24 also can be incorporated into another of FAF1 gene of this sudden change not on the mutational site, and the FAF1 expression of gene of this sudden change still is subjected to the regulation and control of miR-24.In this case, compare with the FAF1 gene that does not have sudden change, the apoptotic ability of the gene induced DU-145 of FAF1 of overexpression sudden change does not have the FAF1 gene of sudden change to strengthen with respect to overexpression.

In this article, object comprises Mammals, its tissue or cell.Mammals comprises people, rat, mouse etc." adjusting " comprises the mediation downward modulation.Adjusting can be to regulate or external adjusting in the body.When regulating in the body, can for example inject etc., give object with composition of the present invention by the various modes of knowing.During external adjusting, can cultivate altogether, the activeconstituents in the composition is entered in vitro tissue or the cell containing the present composition of miR-24 inhibitor and object such as in vitro tissue or cell; Perhaps adopt known technology that activeconstituents is transfected in object such as in vitro tissue or the cell.Regulate and also comprise overexpression miR-24.

In the present invention, the activeconstituents of composition comprises agonist and the inhibitor of miR-24.Agonist can strengthen the expression of miR-24, thereby can suppress the expression of FAF1 better, and the result has suppressed the apoptosis of cell.In another embodiment, realize adjusting by giving the miR-24 inhibitor to FAF1.Inhibitor can suppress the expression of miR-24, increases the expression of FAF1, causes the FAF1 expressing quantity to increase, thereby promotes the apoptosis of cell.The inhibitor of the agonist of the expression of any miR-24 of enhancing and the expression of any miR-24 of inhibition all can be used for the present invention.

Third aspect present invention relates to the apoptotic method of regulating, and this method comprises regulates the FAF1 expression of gene.

In this respect, adjusting also comprises being in harmonious proportion reduces, and promptly for the cell of certain total amount, reduces apoptosis quantity or ratio, or increases apoptosis quantity or ratio.The method of regulating FAF1 genetic expression comprises that (1) is to two miR-24 binding sites enforcement same sense mutations on the FAF1 gene ORF frame, to stop the inhibition of miR-24 to the FAF1 gene; And/or (2) apply agonist or the inhibitor of miR-24; (3) apply FAF1 gene of the present invention or contain the carrier of this gene, perhaps apply the FAF1 gene expression product; And/or (4) overexpression miR-24.

Cell can be for example cell of people, mouse, rat etc. of Mammals.By regulating the apoptosis of cell, can treat tumour.Perhaps,, can make up various animal models for tumour, be used for developing new drug etc. by regulating the apoptosis of cell.

The method that applies the agonist of miR-24 or inhibitor comprises provides the agonist that contains miR-24 or the composition of inhibitor, and with in the said composition body or the external cell that gives; Perhaps in the body or in-vitro transfection go into cell.

The method that foreign DNA is transfected into mammalian cell is that this area is known, is broadly divided into two big class, i.e. biological method and physico-chemical processes.Commonly used in the physico-chemical process have calcium phosphate method, microinjection, electroporation, liposome-mediated transfection, and what occur recently is the gene transmission technology of carrier with the high molecular polymer.Biological method then mainly be with virus as carrier, the mode by virus infection imports to foreign DNA in the cell, and is wherein commonly used with retrovirus and Adenovirus Transfection system.

Calcium phosphate can reach higher transfection efficiency in the isocellular transfection of 293T under good transfection conditions.In addition, transfection method also comprises the cationic-liposome method, and the liposome and the electronegative phosphate group of nucleic acid that are specially positively charged form mixture by cell endocytic.The cationic-liposome that is applicable to the cationic-liposome method is that this area is known, and can buy from various commercial sources.

Fourth aspect present invention comprises the treatment method for cancer, and this method comprises the expression of regulating FAF1, impels the cancer cell apoptosis, thus the treatment cancer.Cancer comprises the various apoptotic cancers that have via the FAF1 mediation, includes but not limited to malignant mesothe, hormone-independent prostate cancer, cervical cancer, cancer of the stomach, colorectal carcinoma and carcinoma of the pancreas etc.The method of regulating the expression of FAF1 comprises that (1) is to two miR-24 binding sites enforcement same sense mutations on the FAF1 gene ORF frame, to stop the inhibition of miR-24 to FAF1 genetic expression; And/or (2) apply the miR-24 inhibitor; Or apply FAF1 expression of gene product (3) and/or apply FAF1 gene of the present invention or contain the carrier of this gene.

Fifth aspect present invention relates to the purposes of miR-24 inhibitor in the cancer of preparation treatment FAF1 gene unconventionality expression.

Thereby the miR-24 inhibitor refers in this article and can stop itself and FAF1 bonded material in conjunction with miR-24, comprises its antisense nucleic acid, for example antisense nucleic acid shown in the SEQ ID NO:4.Can implement different modifications to antisense nucleic acid, lock 2 '-methoxyl group modification that occurred in nucleotide modification and other document etc. as used in this article, perhaps modify at sites different on the antisense nucleic acid.Can all modify each base on the antisense sequences of miR-24 generally speaking with methoxy.Also can the some sites of selective modification.But concrete reference: Angie M.Cheng, Mike W.Byrom, Jeffrey Shelton and Lance P.Ford., " Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis ", Nucleic Acids Res., 2005; 33 (4): 1290-1297; And Wang Q, Huang Z, Xue H, Jin C, Ju XL, Han JD and ChenYG, " MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptorALK4 ", Blood, 2008 Jan 15; 111 (2): 588-95.Epub 2007Sep 28.

In one embodiment, the antisense nucleic acid of miR-24 is the antisense nucleic acid at miR-24 2-8 position (from 5 ' to 3 ') base, and its sequence is 5 '-CTGAGCC-3 '.Can add pairing base in any one or both sides of this sequence corresponding to the miR-24 correspondence position.For example, described antisense nucleic acid can be sequence shown in the SEQ ID NO:4 from 3 ' the 2nd to the sequence the 8th, 9,10,11,12,13,14,15,16,17,18,19,20,21 or 22 bit bases, or SEQ ID NO:4 from 3 ' the 1st to the sequence the 8th, 9,10,11,12,13,14,15,16,17,18,19,20 or 21 bit bases.

The above-mentioned miR-24 antisense nucleic acid that the present invention includes SEQ ID NO:4 and derive and obtain, and the expression cassette that contains arbitrary above-mentioned antisense nucleic acid by SEQ ID NO:4.

Sixth aspect present invention comprises a kind of pharmaceutical composition, and said composition contains the FAF1 gene of the miR-24 inhibitor of safe and effective amount and/or not sudden change or contains this expression carrier, FAF1 gene of the present invention or contain carrier and/or FAF1 expression of gene product (being FAF1 albumen) and the pharmaceutically acceptable vehicle or the vehicle of this gene.As used herein, the composition of " pharmaceutically acceptable " is applicable to people and/or Mammals and does not have excessive bad side reaction (as toxicity, stimulation and transformation reactions), promptly has the material of rational benefit/risk ratio.Term " pharmaceutically acceptable carrier " refers to be used for the treatment of the carrier of agent administration, comprises various vehicle and thinner.This class vehicle comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Usually pharmaceutical preparation should be complementary with administering mode, and pharmaceutical composition of the present invention can be made into the injection form, for example with physiological saline or contain glucose and the aqueous solution of other assistant agents is prepared by ordinary method.Described pharmaceutical composition should be made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity.

Can also contain various suitable chemotherapeutics in the pharmaceutical composition of the present invention, for example be used for the treatment of the chemotherapeutics that the cancer of various FAF1 gene unconventionality expressions is used, for example the reagent star born of the same parents rhzomorph of cell death inducing, 5 FU 5 fluorouracil, mitomycin etc.

In a preferred embodiment, pharmaceutical composition of the present invention contains inhibitor and the cell death inducer of miR-24.In an embodiment, described inductor is star born of the same parents rhzomorphs.

In a preferred embodiment, pharmaceutical composition of the present invention contains the inhibitor of miR-24 and the overexpression vector of FAF1 gene.FAF1 gene in the described overexpression vector can be the not FAF1 gene of sudden change.

Seventh aspect present invention relates to FAF1 gene or the purposes of its expression product in the medicine that preparation is treated or prevention is used by the cancer of FAF1 gene unconventionality expression.Described cancer includes but not limited to malignant mesothe, hormone-independent prostate cancer, cervical cancer, cancer of the stomach, colorectal carcinoma and carcinoma of the pancreas etc.In this respect, described FAF1 gene comprises that there is the gene of same sense mutation in the binding site of miR-24 of the present invention, comprises that also described binding site does not have the gene of sudden change.Especially, the present invention includes FAF1 gene or its expression product purposes in the medicine that preparation is treated or the prevention prostate cancer is used.

Eighth aspect present invention provides a kind of preparation to be used to study the method and the thus obtained animal model of the animal model of cancer mechanism.This method comprises regulates the FAF1 gene of this animal, thereby makes this animal grow tumour, and carries out tumor research with this animal model, comprises drug screening etc.The present invention also comprises the medicine that uses this animal model screening treatment FAF1 cancers mediated, comprise and give this animal model medicine to be screened, and judge that can this medicine make the tumor regression or the healing of this animal model, wherein can make the tumor regression of animal model or the medicine of healing is required medicine.Medicine both can be a nucleic acid molecule, also can be the chemical compound molecule.The method that gives both comprised directly and having given, and for example oral, injection etc. also comprise giving of the method that adopts biotechnologys such as genetic engineering.Those skilled in the art are known to the method that this employing animal model for tumour screens new drug.

Ninth aspect present invention also relates to a kind of test kit, and this test kit contains miR-24 inhibitor and the required reagent of this inhibitor of transfection.Randomly, this test kit also comprises the specification sheets that uses this miR-24 inhibitor transfecting animal cells.Perhaps, test kit contains mutagenic compound, is used on the FAF1 gene ORF frame of pair cell two miR-24 binding sites and implements same sense mutations, and how to use described mutagenic compound to implement the specification sheets of described sudden change.Perhaps, this test kit comprises the inhibitor of miR-24 simultaneously, the reagent that this inhibitor of transfection is required, and be used on the FAF1 gene ORF frame of pair cell mutagenic compound or the mutagenesis instrument that two miR-24 binding sites are implemented same sense mutations, and optional about transfection specification sheets and about the specification sheets of mutagenesis etc.

Method of the present invention comprises the method for non-therapeutic purpose.Do not describe in may be aspect other is other though it will be apparent to one skilled in the art that the above-mentioned content of describing in aspect certain, described content equally also is applicable to the technical scheme of described others; For example, the content of describing transfection in second aspect present invention equally also can be used for others, or the like.That is, will above-mentioned each concrete aspect in each concrete characteristics combination of describing get up the technical scheme of gained also within the scope of the invention.Hereinafter will describe the present invention in the mode of specific embodiment.Following embodiment only is illustrative, and not restrictive.Those skilled in the art can adopt various substitute modes and combination thereof to implement the application's technical scheme under the situation that does not depart from the application's spirit and scope.

Embodiment 1: use the antisense nucleic acid (miR-24-ASO, SEQ ID NO:4) of miR-24 can cause apoptosis in the DU-145 cell and influence the propagation of DU-145 cell

In the DU-145 cell, use the miR-24-ASO of InterferIN transfection reagent (PolyPlus-transfection) transfection 20nM concentration (synthetic by TaKaRa company, sequence is 5 '-ctGTTCCTgctgAACTGAgcCA-3 ', be SEQID NO:4, wherein lowercase represents to lock the position of nucleic acid marking), PI (Sigma) and mark have been used in transfection after the 48 hours annexin V of FITC (Sigma) dyeing.Detect by flow cytometer, find that miR-24-ASO can cause the apoptosis of DU-145 cell, the ratio of apoptosis is about about 10%, and (Fig. 1 a).

For further detect transfection the DU-145 cell of miR-24-ASO to the tolerance degree of apoptosis-induced reagent star born of the same parents rhzomorph, in the DU-145 cell, use the miR-24-ASO of Interfer IN transfection reagent transfection 20nM concentration, apoptosis-induced 2 hours of the star born of the same parents rhzomorph (Sigma) of concentration 1 μ M during transfection added after 48 hours in nutrient solution.Found that transfection the apoptosis ratio of miR-24-ASO be about 49%, and do not have the apoptosis ratio of transfection to have only about 12%.The proof transfection DU-145 cell of miR-24-ASO the susceptibility of star born of the same parents rhzomorph is significantly strengthened (Fig. 1 b).

Then, we have further detected miR-24-ASO to the apoptotic influence of DU-145.The result shows, in transfection after the miR-24-ASO, the multiplication capacity of DU-145 cell obviously weakens (Fig. 1 c).After having dyed miR-24-ASO and miR-24-mimics (Ambion), the DU-145 transit cell detected the ripe level of caspase 8.Later sophisticated caspase 8 showed increased of miR-24-ASO that the result has shown transfection.Caspase 8 levels of cutting substance obviously reduce.Illustrate that miR-24-ASO may be by caspase 8 path cell death inducings (Fig. 1 d).

Embodiment 2:miR-24 is by regulating and control the FAF1 gene in conjunction with two target sites on the open reading frame (ORF) of FAF1 gene

Use following experimental technique, we have found that the FAF1 gene may be the target gene of miR-24.

Use the RNA22 software of IBM Corporation, do not predict the binding site of miR-24 at 3 ' non-translational region of FAF1, but having found the binding site of two miR-24 on the open reading frame of FAF1, is respectively SEQ ID NO:1 1650-1670 position and 2128-2148 position.Find by the homology comparison, the binding site of miR-24 is all very conservative in eight species such as people, mouse, ox, especially 5 of miRNA ' end nearly all is conservative fully (seeing below) on the 2nd to the 8th institute's bonded " seed " zone, further illustrates that miR-24 can (Fig. 2 be a) by these two sites regulation and control FAF1 genes.

3’-GACAAGGACGACUUGACUCGGU-5’has-miR24

||||||||?|?||||||||

5 '-

UGUU

CUUA U--- CUGAG

CA-3 ' homo sapiens (Homo sapiens) B-1

G CAAGC CCUGCCUC- CUGAGCCAHomo sapiens (Homo sapiens) B-2

U CUGA UA- UG CUC A UGAGCCAMouse (Mus musculus) B-1

CCA UUG UU CCU AU CUGAG CAMouse (Mus musculus) B-2

G CA GGC C

UGCCUC- CUGAGCCAOx (Bos taurus) B-1

CUA UUG

CU CUU AU CUGAG

CAOx (Bos taurus) B-2

G CAAGC CCUGCCUC- CUGAGCCAChimpanzee (Pan troglodytes)

CUA UUG

CU CUU AU CUGAG

CAHorse (Equus caballus)

CUA UUG CU CAU AC CUGAG

CAAfrica Pipa pipa (Xenopus tropicali)

CUA UUG CU CAU AC CUGAG

CAAfrica xenopus (Xenopus laevis)

CC CC GCCG CA GCG G- CUGAGCCAFruit bat (Drosophila melano)

In the above-mentioned sequence alignment, boldface type " U " expression G:U pairing, underscore is represented complete complementary sequence.

For further this prediction of checking, the sequence clone that we will contain these two binding sites has arrived 3 ' untranslated zone of the luciferase of pGL3 plasmid (Promega).The plasmid transfection that will contain binding site then enters the 293T cell and after 24 hours the luciferase relative reactivity is detected.The result shows the cell with respect to transfection NC-mimics (Ambion), and the relative reactivity of luciferase obviously reduces (Fig. 2 b) in the cell of transfection miR-24-mimics.This explanation miR-24 can be incorporated into two binding sites predicting on the FAF1 gene and FAF1 is regulated and control.

Whether in the body FAF1 gene is regulated and control in order to detect miR-24, we, and transfection miR-24-mimics and NC-mimics simultaneously if using pcDNA3.1-FAF1 plasmid overexpression FAF1 gene in the 293T cell.In brief, use the method for PCR, with people's cDNA library be template with FAF1 gene amplification rear clone to the pCDNA3.1 plasmid, obtain the pcDNA3.1-FAF1 plasmid, use transfection reagent Lipofectamin2000 (Invitrogen) transfection to arrive cell then.

This pcDNA3.1-FAF1 plasmid of following structure: FAF1 cDNA (NM_007051) is cloned between pcDNA3.1 (-) EcoRI and XhoI site (Invitrogen).Use following primer from people eDNA library, to clone this FAF1cDNA:

5′-GAACTCGAGATTGGCGTCCAACATGGAC-3′(SEQ?ID?NO：5)

5′-GCGCGAATTCTTACTCTTTTGCTTCAAGG-3′(SEQ?ID?NO：6)

Synthetic binding site also is cloned in 3 ' the UTR zone of luciferase in the pGL3 luciferase carrier (Promega).Then as mentioned before, the construction that obtained and PRL-SV40 and miR-24-mimics or NC-mimics (Ambion) cotransfection are gone in the 293T cell.After 48 hours, use double fluorescent enzyme reporter detection system (Promega) to measure luciferase activity (mean values of three groups of parallel tests).

The result shows, in transfection in the cell of miR-24-mimics the expression level of FAF1 be starkly lower than the cell of transfection NC-mimics and only transfection the cell of pcDNA3.1-FAF1 plasmid.And miR-24 is dose-dependent (Fig. 2 d) to the inhibition of FAF1 protein level.Simultaneously, we in transfection pcDNA3.1-FAF1 plasmid and miR-24-mimics later on again transfection miR-24-ASO, and it is (synthetic by TaKaRa company with NC-ASO, 5 '-caCTTATCagtcAGACCAtcGT-3 ', SEQ ID NO:11, lowercase is represented the site of LNA mark) as reference, found that transfection miR-24-ASO has obviously recovered the downward modulation (Fig. 2 c) of miR-24 to the FAF1 gene.These results prove that miR-24 can regulate and control the FAF1 gene in vivo.

In order to prove that further miR-24 regulates and control FAF1 by two binding sites of prediction, we have especially done same sense mutation in " seed " zone to two sites that FAF1 goes up prediction: by the method for PCR with plasmid amplification one circle, we have made up some same sense mutations at the miR-24 of FAF1 gene calmodulin binding domain CaM.Used following sequence as the PCR primer:

FAF1-Mu-B1-FW：5′-TTAGCTACCTCACGCAAAATTTTATAACCTGGGCTT-3′(SEQ?ID?NO：7)

FAF1-Mu-B1-RV：5′-TGCGTGAGGTAGCTAACAATGGATTCAGCACAAAG-3′(SEQ?ID?NO：8)

FAF1-Mu-B2-FW：5′-CTCCCTCCGGAACCTAAGGAAGAAAATGCTGAGCCTG-3′(SEQ?ID?NO：9)

FAF1-Mu-B2-RV：5′-TTAGGTTCCGGAGGGAGGGCTTGCTCTAAGGACAG-3′(SEQ?ID?NO：10)

Go into the FAF1 gene (sudden change that is taken place is with FAF1-M1 and the FAF1-M2 of embodiment 4) of sudden change then to the 293T transit cell, change the miR-24-mimics of different concns simultaneously over to, the result shows, the FAF1 gene that suddenlys change behind commentaries on classics 1nM or 5nMmiR-24-mimics is not reduced, and the FAF1 gene begins downward modulation after changing 20nM miR-24-mimics over to.MiR-24 obviously weakens (Fig. 2 e) to the ability of regulation and control of the FAF1 gene of sudden change.These presentation of results miR-24 can be by two binding site regulation and control FAF1 expression of gene of prediction.

Embodiment 3:miR-24 is by the apoptosis of target FAF1 gene regulating DU-145 cell

In order to detect miR-24 whether the apoptotic regulation and control of DU-145 are undertaken by the FAF1 gene, we in the DU-145 cell respectively cotransfection different reagent.Found that transfection pcDNA3.1-FAF1 overexpression FAF1 gene can equally cause the apoptosis of DU-145 cell to the expression that suppresses miR-24.We transfection miR-24-ASO suppresses the expression of miR-24 then, simultaneously cotransfection pcDNA3.1-FAF1 overexpression FAF1.Found that: overexpression FAF1 gene can be induced the apoptosis (after 48 hours about 70%) of DU-145 cell very efficiently after having suppressed miR-24.For verifying that further miR-24 can control FAF1 to the apoptotic regulation and control of DU-145; we have changed miR-24-mimics overexpression miR-24 in overexpression FAF1, found that overexpression miR-24 can well protect not apoptosis of FAF1 inductive DU-145 cell.These results prove that miR-24 is (Fig. 3) of regulating and control by the apoptosis of target FAF1 gene pairs DU-145 cell.

Embodiment 4: two miR-24 binding sites on the same sense mutation FAF1 gene can be further apoptosis-induced

In order to confirm that further apoptotic influence is to be undertaken by two binding sites that are attached on the FAF1 gene ORF frame to miR-24 to DU-145, with the overexpression vector pcDNA3.1-FAF1-M12 transfection DU-145 cell of sudden change.

The FAF1 overexpression vector pcDNA3.1-FAF1-M12 of two sites of following structure miR-24 bonded seed region sudden change: use PCR method to make up in two steps.The primer that sudden change is used is respectively:

FAF1-Mu-B1-FW：5′-TTAGCTACCTCACGCAAAATTTTATAACCTGGGCTT-3′(SEQ?ID?NO：7)；

FAF1-Mu-B1-RV：5′-TGCGTGAGGTAGCTAACAATGGATTCAGCACAAAG-3′(SEQ?ID?NO：8)；

FAF1-Mu-B2-FW：5′-CTCCCTCCGGAACCTAAGGAAGAAAATGCTGAGCCTG-3′(SEQ?ID?NO：9)：

FAF1-Mu-B2-RV：5′-TTAGGTTCCGGAGGGAGGGCTTGCTCTAAGGACAG-3′(SEQ?ID?NO：10)。

With pcDNA3.1-FAF1 plasmid (making up shown in embodiment 2) is template, makes up the FAF1 expression plasmid pcDNA3.1-FAF1-M1 of first binding site sudden change.The PCR reaction system is:

10×KOD?Buffer 5μl

dNTP(2mM) 5μl

MgSO ₄(20mM) 2μl

FAF1-Mu-B1-FW(20μM) 2μl

FAF1-Mu-B1-RV(20μM) 2μl

Template (pcDNA3.1-FAF1 plasmid) 1 μ l

KOD?plus 1μl

Add H ₂O is to cumulative volume 50 μ l

Use the Eppendorf PCR of company instrument two-step approach to react.The PCR reaction conditions is:

1) 94 ℃, 5 minutes; 2) 94 ℃, 1 minute; 3) 68 ℃, 10 minutes; 4) return 2), carry out 20 and take turns; 5) 68 ℃, 20 minutes; 7) keep 10 ℃.

PCR rear electrophoresis glue reclaims.Use 37 ℃ of enzymes of DpnI restriction enzyme to cut and transform DH5 α bacterial strain after 4 hours.Evaluation obtains the FAF1 expression vector pcDNA3.1-FAF1-M1 of first binding site sudden change.Then with making up identical reaction system and the reaction conditions of first binding site, with the pcDNA3.1-FAF1-M1 plasmid is template, is that primer makes up the FAF1 expression vector pcDNA3.1-FAF1-M12 that all there is sudden change in two sites with FAF1-Mu-B2-FW and FAF1-Mu-B2-RV.

What take place sports:

5’-uuguuAGCuaC---cuCaCGca-3’ FAF1-M1

5’-gcaagcccugccuccGgaAccU-3’ FAF1-M2

FAF1-M1 and FAF1-M2 are the sudden changes of the corresponding homo sapiens B-1 of difference and two binding sites of homo sapiens B-2.Wherein capitalization is represented the site that suddenlys change.454-2406 position among the concrete visible SEQ ID of the sequence NO:12.

With the overexpression vector pcDNA3.1-FAF1-M12 transfection DU-145 cell of sudden change, the result shows that the FAF1 of sudden change can induce about about 34% DU-145 apoptosis after 36 hours, far above the not sudden change FAF1 institute inductive apoptosis of transfection same amount.We have verified further again whether miR-24 can regulate and control the FAF1 gene of sudden change then.We in transfection cotransfection miR-24-mimics in the pcDNA3.1-FAF1-M12; although found that not apoptosis of DU-145 cell that overexpression miR-24 in the experiment in front well protected overexpression FAF1, the DU-145 apoptosis that the miR-24 overexpression but can not stop the FAF1 overexpression of sudden change to cause.These results show that miR-24 is (Fig. 4) of the apoptosis of DU-145 cell being regulated and control by two binding sites that are attached on the FAF1 gene ORF frame.

Embodiment 5:miR-24-ASO can induce the HeLa apoptosis equally and influence the propagation of HeLa cell

Then, we have detected the influence of miR-24-ASO to HeLa cell proliferation simultaneously in the expression that the HeLa transit cell has dyed miR-24-ASO inhibition miR-24.The result shows that the transfection of miR-24-ASO has suppressed the propagation of HeLa cell.We in transfection 48 hours of miR-24-ASO add 1nM later on star born of the same parents rhzomorphs induce the HeLa apoptosis, found that the HeLa cell obviously strengthens the tolerance of star born of the same parents rhzomorph after the expression that suppresses miR-24.These data are told us, and miR-24 pair cell regulation of apoptosis may not only be confined to the DU-145 cell.The expression that suppresses miR-24 may cause later the apoptosis (Fig. 5) of kinds of tumor cells.

Because the DU-145 cell is the insensitive cell of hormone, so these data provide prostate cancer even some other tumor treatment that is used for the insensitive class of hormone that a possible target spot is provided to us.

Embodiment 6:miR-24-ASO suppresses the expression of the endogenous miR-24 of stomach cancer cell

Use Interfer IN transfection reagent respectively in two strain stomach cancer cell HGC-27 and MGC-803 transfection 20nMmiR-24-ASO suppress the expression of endogenous miR-24, the miR-24-ASO of transfection simultaneously " seed site " sudden change, promptly NC-ASO in contrast.Microscopically observation of cell after the transfection 36 hours found that this two strains stomach cancer cell obvious apoptosis all occurs with respect to control group after the expression that suppresses endogenous miR-24.Use Annexin V-FITC and PI to dye, use flow cytometer that the apoptosis degree is carried out quantitative analysis then.Found that the apoptosis that two strain stomach cancer cell HGC-27 and MGC-803 transfection miR-24-ASO are occurred all obviously increases with respect to the level of apoptosis of control group.The early apoptosis rate of HGC-27 after the transfection miR-24-ASO is about 14%, and late period, apoptosis rate was about 10%.High about 3 times approximately with respect to control group.The early apoptosis rate of MGC-803 after the transfection miR-24-ASO is about 13%, and late period, apoptosis rate was about 11%.About respectively high about 2 times and 5 times with respect to control group.The result is presented in Fig. 6 and 7.

The animal model experiment of embodiment 7:miR-24-ASO and AOS-miR-24 treatment tumour

1. material and method

(1) sequence of miR-24 is a RNA sequence of having only 22 Nucleotide shown in SEQ ID NO:3.MiR-24-ASO is the antisense nucleic acid of miR-24, and the complementation of its sequence and miR-24 is shown in SEQ ID NO:4.The sequence of miR-24-ASO is a fixed.But can select to modify different montages or select different modification modes on base, modifying as lock nucleic acid used in literary composition, it also is the modification of using always that 2 ' methoxy is modified.

(2) cell cultures and transfection

Obtain 293T, HeLa and DU-145 cell from the cell bank of the Chinese Academy of Sciences, in DMEM that has replenished 10% foetal calf serum (FBS) or DMEM/F12 at 37 ℃, 5%CO ₂Under cultivate these cells.

For transient transfection, with Lipofectamine 2000 (Invitrogene) will degree of being paved be different concns on 70% the cell transfecting synthetic miRNA-mimics, negative control (NC-mimics) (Ambion), widow-ribonucleotide miR-24-ASO and the NC-ASO (TaKaRa) of LNA mark and the plasmid that is worth according to standard scheme of synthetic LNA mark.After the transfection,, carry out biochemistry or biological analysis at the different time points collecting cell.

The sequence of the NC-ASO of LNA mark is 5 '-caCTTATCagtcAGACCAtcGT-3 ' (SEQ ID NO:11); The sequence of the oligoribonucleotide miR-24-ASO of LNA mark is 5 '-ctGTTCCTgctgAACTGAgcCA-3 '; Lowercase alphabet shows the site of LNA mark in the above-mentioned sequence.

(3) plasmid construction

This pcDNA3.1-FAF1 plasmid of following structure: FAF1 cDNA (NM_007051) is cloned between pcDNA3.1 (-) EcoRI and XhoI site (Invitrogen).Use following primer from the human cDNA library, to clone this FAF1cDNA:

5′-GAACTCGAGATTGGCGTCCAACATGGAC-3′(SEQ?ID?NO：5)

5′-GCGCGAATTCTTACTCTTTTGCTTCAAGG-3′(SEQ?ID?NO：6)。

Adopt aforementioned primer SEQ ID NOS:7-10, be structured in the several FAF1 mutant that have sudden change in the miR-24 binding site by PCR method.

(4) luciferase detects

Synthetic binding site also is cloned in 3 ' the UTR zone of luciferase in the pGL3 luciferase carrier (Promega).Then as mentioned before, the construction that obtained and PRL-SV40 and miR-24-mimics or NC-mimics (Ambion) cotransfection are gone in the 293T cell.After 48 hours, use double fluorescent enzyme reporter detection system (Promega) to measure luciferase activity (mean values of three groups of parallel tests).

(5) apoptosis analysis

With different synthetic oligonucleotides or different carrier transfection DU-145 cell and HeLa cells.The extra cultivation after 36 hours or 48 hours, collecting cell with the anti-annexin-V antibody staining of iodate third ingot and FITC mark, is used facs analysis then.

(6) cell proliferation detects

Using cell counting test kit-8 (Dojindo) to carry out cell proliferation detects.With cell inoculation on 24 hole flat boards, every hole about 5 * 10 ⁴Individual cell, and in growth medium, cultivate.At the appointed time put with the absorbancy (450nm) of reductive WST-8 (2-(2-methoxyl group-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-two sulfophenyls)-2H-tetrazolium list sodium salt) and measure cell quantity in three groups of parallel test holes.

(7) proteins extraction and western blotting

With 1 * SDS Loading damping fluid (Sigma) collecting cell.Protein isolate on the SDS-polyacrylamide gel is transferred to pvdf membrane then.Then, with at room temperature blockade film 1 hour of 5% skimmed milk powder (use PBST dissolving), then make in its 1% skim-milk in containing the TTBS of first antibody (the Tris damping fluid that contains 1% tween) 4 ℃ to spend the night with TTBS (the Tris damping fluid that contains 1% tween).(Pierce) detect first antibody with peroxidase link coupled second antibody (Sigma) and chemoluminescence (ECL).Use following first antibody: anti-FAF of rabbit (Cell signaling) and GAPDH (Abcam).

(8) animal model test

At first at nude mice subcutaneous vaccination prostate cancer tumor piece than tumour cell suspension, set up the prostate cancer tumor model.

Become after the knurl virus vector of in the knurl piece of experimental mice injection miR-24-ASO or FAF1-M12 gene or both to inject simultaneously, simultaneously with NC-ASO and/or the virus vector that does not contain the FAF1 gene organize in contrast.

After some days, take out the tumour lump and observe lump size and shape.The prostate cancer marrow transfer case of test experience group and nude mice of control group is with the effect of checking medicine to the prostate cancer transfer ability in addition.

2. experimental result

The intravital knurl piece of mouse after being expected at the virus vector of injection miR-24-ASO or FAF1-M12 gene or both and injecting simultaneously with respect to the knurl piece of control group at volume with can diminish qualitatively.The metastases ability of injectable drug group obviously reduces with respect to control group.

Discuss

The application finds that miR-24 can regulate and control the expression level of FAF1 by the CDS zone that is attached to FAF1, thereby further regulates and control the apoptosis of DU-145 cell.Found simultaneously that miR-24-ASO can induce the apoptosis of DU-145 cell and HeLa cell, deepened our understanding Faf1 regulating cell apoptosis pathway.

The DU-145 cell is the people's of the classics separated from the prostate cancer brain shifts a prostate cancer cell line.During it has can transitivity, do not express prostate specific antigen (PSA) and be the prostate cancer cell of non-hormone dependence.For the hormonal dependent prostate cancer, can reach good result of treatment by hormonotherapies such as castration, androgen antagonist medicines.But to the non-hormone dependence prostate cancer, present still good without comparison therapy.The apoptosis that the application finds miR-24-ASO, pcDNA3.1-FAF1-M12 and the FAF1 gene of overexpression all can well be induced the DU-145 cell after miR-24-ASO suppresses the miR-24 expression.Especially the back both, apoptosis rate has reached respectively about 34% and 70%.These experimental results provide good clue for us by miR-24/FAF1 path treatment non-hormone dependence prostate cancer.

MiR24 is a microRNA very big with the human tumor dependency.Be not only because he can suppress the expression of cancer suppressor gene p16, some researchs before simultaneously also find the unconventionality expression of miR-24 in some tumor types.These all show miR-24 may be an oncogene microRNA.Our result of study finds that miR-24 can regulate and control the apoptosis of DU-145 cell and HeLa cell, illustrates that miR-24/FAF1 path modulate tumor apoptosis may be a general apoptosis of tumor cells regulatory mechanism.

In sum, our miR-24 that discovers can regulate and control the FAF1 gene by two binding sites on the ORF frame that is attached to FAF1.The expression of the miR-24 of miR-24-ASO inhibition simultaneously can be induced the apoptosis of DU-145 cell.Our research has proved that further microRNA can be incorporated into the zone regulation and control in addition of 3 ' non-translational region the theory of memory.Simultaneously, our research is that non-hormone dependence prostate cancer and other treatment for cancer are put forward potential target site and the medicinal application prospect controlled.

Sequence table

＜110〉Shanghai Inst. of Life Science, CAS

＜120〉method and composition of regulation and control FAF1 gene and the purposes of described composition

<130>090898

<160>12

<170>PatentIn?version?3.3

<210>1

<211>2610

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>1

caggggcgga?ggcggcggcc?agggaggaag?cggaggaggc?ggaggcggcc?gcggcgttcg 60

cccgcccgct?cgctcgctcg?gtttccccgc?ccccgccggg?cttaacgccg?ctgaaggtat 120

ccgggtgcgc?gctgtcgcaa?cctgccctca?tcctggcccg?cgactgtaag?accggaccca 180

catccagacc?aatcttcctg?tccgggctgc?tgcgacgcgg?gctccgcagg?ttgcaggcgg 240

gcggccgggg?cgcctgaagg?ttaccgagtg?catgagcgcc?tagcgcttcc?cgcgctgccc 300

cgcccgctgg?cccgccgacc?cgcccgccgg?ctcgcccgcc?agcccctcgg?cgcccggcgg 360

cggcggcggc?ggtggcggcg?acggtcgcag?gaggtgccgt?ctgcctccca?ggtgcgcgct 420

tcgctcccgg?agccgcggaa?ctcggcggcc?gccatggcgt?ccaacatgga?ccgggagatg 480

atcctggcgg?attttcaggc?atgtactggc?attgaaaaca?ttgacgaagc?tattacattg 540

cttgaacaaa?ataattggga?cttagtggca?gctatcaatg?gtgtaatacc?acaggaaaat 600

ggcattctac?aaagtgaata?tggaggtgag?accataccag?gacctgcatt?taatccagca 660

agtcatccag?cttcagctcc?tacttcctct?tcttcttcag?cgtttcgacc?tgtaatgcca 720

tccaggcaga?ttgtagaaag?gcaacctcgg?atgctggact?tcagggttga?atacagagac 780

agaaatgttg?atgtggtact?tgaagacacc?tgtactgttg?gagagattaa?acagattcta 840

gaaaatgaac?ttcagatacc?tgtgtccaaa?atgctgttaa?aaggctggaa?gacgggagat 900

gtggaagaca?gtacggtcct?aaaatctcta?cacttgccaa?aaaacaacag?tctttatgtc 960

cttacaccag?atttgccacc?accttcatca?tctagtcatg?ctggtgccct?gcaggagtca 1020

ttaaatcaaa?acttcatgct?gatcatcacc?caccgagaag?tccagcggga?gtacaacctg 1080

aacttctcag?gaagcagtac?tattcaagag?gtaaagagaa?atgtgtatga?ccttacaagt 1140

atccccgttc?gccaccaatt?atgggagggc?tggccaactt?ctgctacaga?cgactcaatg 1200

tgtcttgctg?aatcagggct?ctcttatccc?tgccatcgac?ttacagtggg?aagaagatct 1260

tcacctgcac?agacccggga?acagtcggaa?gaacaaatca?ccgatgttca?tatggttagt 1320

gatagcgatg?gagatgactt?tgaagatgct?acagaatttg?gggtggatga?tggagaagta 1380

tttggcatgg?cgtcatctgc?cttgagaaaa?tctccaatga?tgccagaaaa?cgcagaaaat 1440

gaaggagatg?ccttattaca?atttacagca?gagttttctt?caagatatgg?tgattgccat 1500

cctgtatttt?ttattggctc?attagaagct?gcttttcaag?aggccttcta?tgtgaaagcc 1560

cgagatagaa?agcttcttgc?tatctacctc?caccatgatg?aaagtgtgtt?aaccaacgtg 1620

ttctgctcac?aaatgctttg?tgctgaatcc?attgtttctt?atctgagtca?aaattttata 1680

acctgggctt?gggatctgac?aaaggactcc?aacagagcaa?gatttctcac?tatgtgcaat 1740

agacactttg?gcagtgttgt?ggcacaaacc?attcggactc?aaaaaacgga?tcagtttccg 1800

cttttcctga?ttattatggg?aaagcgatca?tctaatgaag?tgttgaatgt?gatacaaggg 1860

aacacaacag?tagatgagtt?aatgatgaga?ctcatggctg?caatggagat?cttcacagcc 1920

caacaacagg?aagatataaa?ggacgaggat?gaacgtgaag?ccagagaaaa?tgtgaagaga 1980

gagcaagatg?aggcctatcg?cctttcactt?gaggctgaca?gagcaaagag?ggaagctcac 2040

gagagagaga?tggcagaaca?gtttcgtttg?gagcagattc?gcaaagaaca?agaagaggaa 2100

cgtgaggcca?tccggctgtc?cttagagcaa?gccctgcctc?ctgagccaaa?ggaagaaaat 2160

gctgagcctg?tgagcaaact?gcggatccgg?acccccagtg?gcgagttctt?ggagcggcgt 2220

ttcctggcca?gcaacaagct?ccagattgtc?tttgattttg?tagcttccaa?aggatttcca 2280

tgggatgagt?acaagttact?gagcaccttt?cctaggagag?acgtaactca?actggaccca 2340

aataaatcat?tattggaggt?aaagttgttc?cctcaagaaa?cccttttcct?tgaagcaaaa 2400

gagtaaacac?ggcccagcgg?tggaaccagc?cattccttga?caagccagca?gcctgcgtca 2460

ggagaagggc?tcctcgccaa?cccacccaca?cgctcgtctc?actcaattca?atgtcacact 2520

tctgcctctt?gcaaaattgc?tggaaaaagt?aataataaat?atagctactt?aagatttccc 2580

atcaaaaaaa?aaaaaaaaaa?aaaaaaaaaa 2610

<210>2

<211>650

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>2

Met?Ala?Ser?Asn?Met?Asp?Arg?Glu?Met?Ile?Leu?Ala?Asp?Phe?Gln?Ala

1 5 10 15

Cys?Thr?Gly?Ile?Glu?Asn?Ile?Asp?Glu?Ala?Ile?Thr?Leu?Leu?Glu?Gln

20 25 30

Asn?Asn?Trp?Asp?Leu?Val?Ala?Ala?Ile?Asn?Gly?Val?Ile?Pro?Gln?Glu

35 40 45

Asn?Gly?Ile?Leu?Gln?Ser?Glu?Tyr?Gly?Gly?Glu?Thr?Ile?Pro?Gly?Pro

50 55 60

Ala?Phe?Asn?Pro?Ala?Ser?His?Pro?Ala?Ser?Ala?Pro?Thr?Ser?Ser?Ser

65 70 75 80

Ser?Ser?Ala?Phe?Arg?Pro?Val?Met?Pro?Ser?Arg?Gln?Ile?Val?Glu?Arg

85 90 95

Gln?Pro?Arg?Met?Leu?Asp?Phe?Arg?Val?Glu?Tyr?Arg?Asp?Arg?Asn?Val

100 105 110

Asp?Val?Val?Leu?Glu?Asp?Thr?Cys?Thr?Val?Gly?Glu?Ile?Lys?Gln?Ile

115 120 125

Leu?Glu?Asn?Glu?Leu?Gln?Ile?Pro?Val?Ser?Lys?Met?Leu?Leu?Lys?Gly

130 135 140

Trp?Lys?Thr?Gly?Asp?Val?Glu?Asp?Ser?Thr?Val?Leu?Lys?Ser?Leu?His

145 150 155 160

Leu?Pro?Lys?Asn?Asn?Ser?Leu?Tyr?Val?Leu?Thr?Pro?Asp?Leu?Pro?Pro

165 170 175

Pro?Ser?Ser?Ser?Ser?His?Ala?Gly?Ala?Leu?Gln?Glu?Ser?Leu?Asn?Gln

180 185 190

Asn?Phe?Met?Leu?Ile?Ile?Thr?His?Arg?Glu?Val?Gln?Arg?Glu?Tyr?Asn

195 200 205

Leu?Asn?Phe?Ser?Gly?Ser?Ser?Thr?Ile?Gln?Glu?Val?Lys?Arg?Asn?Val

210 215 220

Tyr?Asp?Leu?Thr?Ser?Ile?Pro?Val?Arg?His?Gln?Leu?Trp?Glu?Gly?Trp

225 230 235 240

Pro?Thr?Ser?Ala?Thr?Asp?Asp?Ser?Met?Cys?Leu?Ala?Glu?Ser?Gly?Leu

245 250 255

Ser?Tyr?Pro?Cys?His?Arg?Leu?Thr?Val?Gly?Arg?Arg?Ser?Ser?Pro?Ala

260 265 270

Gln?Thr?Arg?Glu?Gln?Ser?Glu?Glu?Gln?Ile?Thr?Asp?Val?His?Met?Val

275 280 285

Ser?Asp?Ser?Asp?Gly?Asp?Asp?Phe?Glu?Asp?Ala?Thr?Glu?Phe?Gly?Val

290 295 300

Asp?Asp?Gly?Glu?Val?Phe?Gly?Met?Ala?Ser?Ser?Ala?Leu?Arg?Lys?Ser

305 310 315 320

Pro?Met?Met?Pro?Glu?Asn?Ala?Glu?Asn?Glu?Gly?Asp?Ala?Leu?Leu?Gln

325 330 335

Phe?Thr?Ala?Glu?Phe?Ser?Ser?Arg?Tyr?Gly?Asp?Cys?His?Pro?Val?Phe

340 345 350

Phe?Ile?Gly?Ser?Leu?Glu?Ala?Ala?Phe?Gln?Glu?Ala?Phe?Tyr?Val?Lys

355 360 365

Ala?Arg?Asp?Arg?Lys?Leu?Leu?Ala?Ile?Tyr?Leu?His?His?Asp?Glu?Ser

370 375 380

Val?Leu?Thr?Asn?Val?Phe?Cys?Ser?Gln?Met?Leu?Cys?Ala?Glu?Ser?Ile

385 390 395 400

Val?Ser?Tyr?Leu?Ser?Gln?Asn?Phe?Ile?Thr?Trp?Ala?Trp?Asp?Leu?Thr

405 410 415

Lys?Asp?Ser?Asn?Arg?Ala?Arg?Phe?Leu?Thr?Met?Cys?Asn?Arg?His?Phe

420 425 430

Gly?Ser?Val?Val?Ala?Gln?Thr?Ile?Arg?Thr?Gln?Lys?Thr?Asp?Gln?Phe

435 440 445

Pro?Leu?Phe?Leu?Ile?Ile?Met?Gly?Lys?Arg?Ser?Ser?Asn?Glu?Val?Leu

450 455 460

Asn?Val?Ile?Gln?Gly?Asn?Thr?Thr?Val?Asp?Glu?Leu?Met?Met?Arg?Leu

465 470 475 480

Met?Ala?Ala?Met?Glu?Ile?Phe?Thr?Ala?Gln?Gln?Gln?Glu?Asp?Ile?Lys

485 490 495

Asp?Glu?Asp?Glu?Arg?Glu?Ala?Arg?Glu?Asn?Val?Lys?Arg?Glu?Gln?Asp

500 505 510

Glu?Ala?Tyr?Arg?Leu?Ser?Leu?Glu?Ala?Asp?Arg?Ala?Lys?Arg?Glu?Ala

515 520 525

His?Glu?Arg?Glu?Met?Ala?Glu?Gln?Phe?Arg?Leu?Glu?Gln?Ile?Arg?Lys

530 535 540

Glu?Gln?Glu?Glu?Glu?Arg?Glu?Ala?Ile?Arg?Leu?Ser?Leu?Glu?Gln?Ala

545 550 555 560

Leu?Pro?Pro?Glu?Pro?Lys?Glu?Glu?Asn?Ala?Glu?Pro?Val?Ser?Lys?Leu

565 570 575

Arg?Ile?Arg?Thr?Pro?Ser?Gly?Glu?Phe?Leu?Glu?Arg?Arg?Phe?Leu?Ala

580 585 590

Ser?Asn?Lys?Leu?Gln?Ile?Val?Phe?Asp?Phe?Val?Ala?Ser?Lys?Gly?Phe

595 600 605

Pro?Trp?Asp?Glu?Tyr?Lys?Leu?Leu?Ser?Thr?Phe?Pro?Arg?Arg?Asp?Val

610 615 620

Thr?Gln?Leu?Asp?Pro?Asn?Lys?Ser?Leu?Leu?Glu?Val?Lys?Leu?Phe?Pro

625 630 635 640

Gln?Glu?Thr?Leu?Phe?Leu?Glu?Ala?Lys?Glu

645 650

<210>3

<211>22

<212>RNA

＜213〉homo sapiens (Homo sapiens)

<400>3

uggcucaguu?cagcaggaac?ag 22

<210>4

<211>22

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

<223>miR-24-ASO

<400>4

ctgttcctgc?tgaactgagc?ca 22

<210>5

<211>28

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

＜223〉primer

<400>5

gaactcgaga?ttggcgtcca?acatggac 28

<210>6

<211>29

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

＜223〉primer

<400>6

gcgcgaattc?ttactctttt?gcttcaagg 29

<210>7

<211>36

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

＜223〉primer

<400>7

ttagctacct?cacgcaaaat?tttataacct?gggctt 36

<210>8

<211>35

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

＜223〉primer

<400>8

tgcgtgaggt?agctaacaat?ggattcagca?caaag 35

<210>9

<211>37

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

＜223〉primer

<400>9

ctccctccgg?aacctaagga?agaaaatgct?gagcctg 37

<210>10

<211>35

<212>DNA

＜213〉artificial sequence

<220>

<221>misc_feature

＜223〉primer

<400>10

ttaggttccg?gagggagggc?ttgctctaag?gacag 35

<210>11

<211>22

<212>DNA

<213>NC-ASO

<400>11

cacttatcag?tcagaccatc?gt 22

<210>12

<211>2610

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>12

caggggcgga?ggcggcggcc?agggaggaag?cggaggaggc?ggaggcggcc?gcggcgttcg 60

cccgcccgct?cgctcgctcg?gtttccccgc?ccccgccggg?cttaacgccg?ctgaaggtat 120

ccgggtgcgc?gctgtcgcaa?cctgccctca?tcctggcccg?cgactgtaag?accggaccca 180

catccagacc?aatcttcctg?tccgggctgc?tgcgacgcgg?gctccgcagg?ttgcaggcgg 240

gcggccgggg?cgcctgaagg?ttaccgagtg?catgagcgcc?tagcgcttcc?cgcgctgccc 300

cgcccgctgg?cccgccgacc?cgcccgccgg?ctcgcccgcc?agcccctcgg?cgcccggcgg 360

cggcggcggc?ggtggcggcg?acggtcgcag?gaggtgccgt?ctgcctccca?ggtgcgcgct 420

tcgctcccgg?agccgcggaa?ctcggcggcc?gccatggcgt?ccaacatgga?ccgggagatg 480

atcctggcgg?attttcaggc?atgtactggc?attgaaaaca?ttgacgaagc?tattacattg 540

cttgaacaaa?ataattggga?cttagtggca?gctatcaatg?gtgtaatacc?acaggaaaat 600

ggcattctac?aaagtgaata?tggaggtgag?accataccag?gacctgcatt?taatccagca 660

agtcatccag?cttcagctcc?tacttcctct?tcttcttcag?cgtttcgacc?tgtaatgcca 720

tccaggcaga?ttgtagaaag?gcaacctcgg?atgctggact?tcagggttga?atacagagac 780

agaaatgttg?atgtggtact?tgaagacacc?tgtactgttg?gagagattaa?acagattcta 840

gaaaatgaac?ttcagatacc?tgtgtccaaa?atgctgttaa?aaggctggaa?gacgggagat 900

gtggaagaca?gtacggtcct?aaaatctcta?cacttgccaa?aaaacaacag?tctttatgtc 960

cttacaccag?atttgccacc?accttcatca?tctagtcatg?ctggtgccct?gcaggagtca 1020

ttaaatcaaa?acttcatgct?gatcatcacc?caccgagaag?tccagcggga?gtacaacctg 1080

aacttctcag?gaagcagtac?tattcaagag?gtaaagagaa?atgtgtatga?ccttacaagt 1140

atccccgttc?gccaccaatt?atgggagggc?tggccaactt?ctgctacaga?cgactcaatg 1200

tgtcttgctg?aatcagggct?ctcttatccc?tgccatcgac?ttacagtggg?aagaagatct 1260

tcacctgcac?agacccggga?acagtcggaa?gaacaaatca?ccgatgttca?tatggttagt 1320

gatagcgatg?gagatgactt?tgaagatgct?acagaatttg?gggtggatga?tggagaagta 1380

tttggcatgg?cgtcatctgc?cttgagaaaa?tctccaatga?tgccagaaaa?cgcagaaaat 1440

gaaggagatg?ccttattaca?atttacagca?gagttttctt?caagatatgg?tgattgccat 1500

cctgtatttt?ttattggctc?attagaagct?gcttttcaag?aggccttcta?tgtgaaagcc 1560

cgagatagaa?agcttcttgc?tatctacctc?caccatgatg?aaagtgtgtt?aaccaacgtg 1620

ttctgctcac?aaatgctttg?tgctgaatcc?attgttagct?acctcacgca?aaattttata 1680

acctgggctt?gggatctgac?aaaggactcc?aacagagcaa?gatttctcac?tatgtgcaat 1740

agacactttg?gcagtgttgt?ggcacaaacc?attcggactc?aaaaaacgga?tcagtttccg 1800

cttttcctga?ttattatggg?aaagcgatca?tctaatgaag?tgttgaatgt?gatacaaggg 1860

aacacaacag?tagatgagtt?aatgatgaga?ctcatggctg?caatggagat?cttcacagcc 1920

caacaacagg?aagatataaa?ggacgaggat?gaacgtgaag?ccagagaaaa?tgtgaagaga 1980

gagcaagatg?aggcctatcg?cctttcactt?gaggctgaca?gagcaaagag?ggaagctcac 2040

gagagagaga?tggcagaaca?gtttcgtttg?gagcagattc?gcaaagaaca?agaagaggaa 2100

cgtgaggcca?tccggctgtc?cttagagcaa?gccctgcctc?cggaacctaa?ggaagaaaat 2160

gctgagcctg?tgagcaaact?gcggatccgg?acccccagtg?gcgagttctt?ggagcggcgt 2220

ttcctggcca?gcaacaagct?ccagattgtc?tttgattttg?tagcttccaa?aggatttcca 2280

tgggatgagt?acaagttact?gagcaccttt?cctaggagag?acgtaactca?actggaccca 2340

aataaatcat?tattggaggt?aaagttgttc?cctcaagaaa?cccttttcct?tgaagcaaaa 2400

gagtaaacac?ggcccagcgg?tggaaccagc?cattccttga?caagccagca?gcctgcgtca 2460

ggagaagggc?tcctcgccaa?cccacccaca?cgctcgtctc?actcaattca?atgtcacact 2520

tctgcctctt?gcaaaattgc?tggaaaaagt?aataataaat?atagctactt?aagatttccc 2580

atcaaaaaaa?aaaaaaaaaa?aaaaaaaaaa 2610

Claims (10)

1. isolating FAF1 gene, it is characterized in that, the nucleotide sequence of aminoacid sequence shown in this FAF1 genes encoding SEQ ID NO:2, wherein, there are the described 1650-1670 position of one or more bases and SEQ ID NO:1 and/or 2128-2148 bit base to compare in this nucleotide sequence in the base corresponding to SEQ ID NO:1 1650-1670 position and/or 2128-2148 bit base same sense mutation has taken place.

2. FAF1 gene as claimed in claim 1, it is characterized in that, the nucleotide sequence of described isolating FAF1 gene is shown in SEQ ID NO:1 454-2406 position, but the sequence numbering with SEQ ID NO:1 is as the criterion, and same sense mutation has taken place for 1650-1670 position wherein and/or the one or more Nucleotide in the 2128-2148 position.

3. FAF1 gene as claimed in claim 1 is characterized in that the nucleotide sequence of described gene is shown in the 454-2406 position of SEQ ID NO:12.

4. the FAF1 gene of sudden change or the described isolating FAF1 gene of claim 1 purposes in the medicine that preparation treatment or preventing cancer are used not.

5.miR-24 composition of using in preparation treatment or preventing cancer or the purposes in the test kit.

6.miR-24 composition that inhibitor is used in preparation treatment or preventing cancer or the purposes in the test kit.

7. purposes as claimed in claim 6 is characterized in that, described miR-24 inhibitor is the antisense nucleic acid of miR-24.

8. an expression vector is characterized in that, this expression vector contains the FAF1 gene or the described isolating FAF1 gene of claim 1 of not sudden change.

9. pharmaceutical composition, said composition contains

(a) safe and effective amount:

The miR-24 inhibitor; And/or

Not Tu Bian FAF1 gene or its overexpression vector, or described FAF1 gene of claim 1 or the described carrier of claim 8;

And/or FAF1 expression of gene product and

(b) pharmaceutically acceptable vehicle or vehicle.

10. the method for FAF1 expression of gene in the external regulating cell is characterized in that described method comprises:

(1) suppress the expression of miR-24 in this cell, and/or

(2) the miR-24 binding site in the FAF1 gene is implemented same sense mutation; And/or

(3) apply FAF1 gene or its overexpression vector, the described isolating FAF1 gene of claim 1 or the described expression vector of claim 8 that does not suddenly change; And/or

(4) apply FAF1 expression of gene product; Or

(5) overexpression miR-24.

Images